ArticleJournal of virology2026
Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the Role of microRNA in Host-Influenza A and Other Respiratory RNA Virus Interactions.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza viruses represent a significant threat to global public health. MicroRNAs (miRNAs), a class of small non-coding RNA molecules, play pivotal roles in regulating gene expression and have emerged as critical modulators of host-virus interactions. To investigate the functions of miRNAs during influenza virus infection, a miRNA library was constructed and sequenced using DF1 cells infected with the H9N2 influenza virus. From the differentially expressed miRNAs, we identified miR-92 as a key antiviral host factor. Mechanistically, miR-92 inhibits viral replication by targeting TNFRSF1B, which, in turn, enhances type I interferon signaling responses. Promoter region analysis demonstrated that the transcription factor OCT1 binds to the miR-92 promoter and positively regulates its transcriptional activity. Additionally, our study revealed that TNFRSF1B interacts with TNF receptor-associated factor 3 (TRAF3) and mediates TRAF3 degradation via the autophagolysosomal pathway. Specifically, TNFRSF1B facilitates the removal of K63-linked polyubiquitin chains from TRAF3. Collectively, these findings indicate that TNFRSF1B negatively regulates IFN-I responses through autophagolysosomal-mediated TRAF3 degradation, while miR-92 counteracts this inhibitory effect to exert antiviral activity. In summary, our research delineates a novel regulatory axis that modulates the interferon pathway and H9N2 influenza virus replication, providing new insights into host antiviral defense mechanisms and potential therapeutic targets.IMPORTANCEThe miR-17-92 cluster is a well-established key regulator of viral infection. However, the specific role of miR-92, an essential member of this cluster, in modulating avian influenza virus infection remains poorly defined. Here, we demonstrate that avian miR-92 exerts robust antiviral activity by directly inhibiting AIV replication. Critically, we report for the first time that the transcription factor OCT1 binds to the promoter region of miR-92 and transcriptionally regulates its expression. Mechanistically, miR-92 targets TNFRSF1B to enhance type I interferon production. Strikingly, TNFRSF1B mediates the degradation of TRAF3, thereby dampening IFN-I signaling. Together, our findings establish miR-92 as a pivotal antiviral effector during AIV infection. Beyond advancing our understanding of small RNA-mediated control of influenza virus replication, this work identifies miR-92 and its regulatory network as promising targets for the development of miRNA-based antiviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.